xT 648

Targeted NGS panel of 648 genes for Solid Tumors and Hematology

A Test for Every Cancer Patient

Welcome to the future of genomic driven cancer care.

Genomic footprint is used to personalize and optimize cancer treatments. Our genomic test investigate patients tumor at the molecular level to identify best treatment options for each and every patient.

It's about time!

Targeted xT 648 panel is enriched for clinically relevant genes and most commonly mutated cancer driver genes with additional genes of emerging clinical significance focused on immediately actionable mutations.

This NGS assay is composed of 648 genes relevant to the diagnosis, prognosis, and therapeutic targeting of solid tumors and haematological malignancies. It includes DNA Sequence, RNA full transcriptome, and four major classes of genomic alterations; SNVs/SNPs, fusions, indels, and CNVs.

Tumor Mutational Burden testing is now a standard component of the xT 648 Profile. It measures the quantity of somatic mutations, and tumors with higher TMB have an increased likelihood of response to immunotherapy.

Microsatellite Instability Analysis is routinely performed with Colorectal, Endometrial, Esophageal, Gastric, GI Predictive, Ovarian, and Pancreas Profiles, and is included in xT 648 Gene Panel.

PD-L1 is performed is routinely performed with xT 648 Gene Panel. This test is indicated as an aid in identifying NSCLC patients for treatment with KEYTRUDA (pembrolizumab).

Sample requirement is patient FFPE tumor tissue for solid tumors and blood for hematology.

The importance of genomic sequencing.

xT 648 panel integrates data and technology into clinical care.